

Related AF projects

Project	PI	Sponsor
Anti-inflammatory effects on atrial EP	Van Wagoner	NIH HL-65412 (renewal pending)
Ranolazine effects on human atrial Na currents	Van Wagoner	CV Therapeutics
Lone AF genetics, whole genome analysis	Chung	NIH (pending)
n3 FAs for post-op AF prevention	Chung	Reliant Pharma
Statins for AF prevention	Chung	Astra-Zeneca

Related Project: Ranolazine effects on human atrial EP

- Investigator initiated, industry sponsored study to evaluate:
- Evaluate the density of “late I_{Na}” in human atrial myocytes from control and AF patients
- Evaluate the concentration and frequency dependent effects of the novel anti-anginal agent *ranolazine* on sodium currents and action potentials in left atrial myocytes isolated from surgical patients
- Possible mechanistic insights into a novel therapy for AF

Related Project: n3 fatty acids for prevention of post-op AF

- **(Chung, Gillinov, Van Wagoner)**
- **Investigator initiated, industry sponsored multisite clinical trial with sponsor (Reliant Pharmaceutical) holding IND**
 - **Goal: ~250 post cardiac surgery patients**
 - **150 pts at CCF**
 - **Examine plasma and tissue lipids and inflammatory markers**
 - **2 days pretreatment, 1 week post-op f/u**
 - **Endpoint: occurrence of post-op AF**

Summary

- **Our AFIC program has made novel advances in studying the impact of inflammation on atrial histology, in a well characterized group of patients.**
- **We will soon couple this with information on the effects of underlying disease and systemic inflammation on atrial gene expression and genetic variability**
- **With completion of epicardial mapping system, will be able to provide a comprehensive assessment of left atrial genetics, biochemistry, integrated EP, cellular EP, post-operative arrhythmia, and relation of ectopy to plasma inflammatory markers**